遗传性血管性水肿治疗方式与疾病负担研究进展

doi:10.35541/cjd.20220205

中华皮肤科杂志 ›› 2024, e20220205.doi: 10.35541/cjd.20220205

• 综述 • 下一篇

遗传性血管性水肿治疗方式与疾病负担研究进展

刘佳^1，2 谷映桦^1，2 贺小宁^1，2

¹天津大学药物科学与技术学院，天津 300072；²天津大学社会科学调查与数据中心，天津 300072

收稿日期:2022-03-29 修回日期:2023-03-27 发布日期:2024-03-11
通讯作者: 贺小宁 E-mail:hexn@tju.edu.cn

Treatment and disease burden of hereditary angioedema

Liu Jia^1,2, Gu Yinghua^1,2, He Xiaoning^1,2

¹School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China; ²Center for Social Survey and Data, Tianjin University, Tianjin 300072, China

Received:2022-03-29 Revised:2023-03-27 Published:2024-03-11
Contact: He Xiaoning E-mail:hexn@tju.edu.cn

摘要/Abstract

摘要： 【摘要】遗传性血管性水肿（HAE）是一种常染色体显性遗传病，主要表现为皮肤和黏膜水肿，其全球患病率约为1/50 000，我国目前尚缺乏相关流行病学数据。作为一种罕见病，HAE在临床和社会中的认知度至今仍然很低，因此常被误诊、误治，严重影响患者的生活质量和寿命，为家庭和社会带来沉重的经济负担。本研究对HAE的流行病学、治疗方式、患者经济负担以及患者健康相关生命质量进行梳理与总结，旨在促进临床医生及医疗卫生决策者充分认识HAE。

关键词: 血管水肿, 遗传性, 患病代价, 治疗, 生活质量

Abstract: 【Abstract】 Hereditary angioedema （HAE） is an autosomal dominant genetic disease characterized by swelling of the skin and mucosa. The global prevalence of HAE is about 1/50 000, but relevant epidemiological data are still lacking in China. As a rare disease, HAE is still poorly recognized in clinical practice and society, often leading to misdiagnosis and incorrect treatment. Moreover, it seriously affects the quality of life and lifespan of patients, and brings a heavy economic burden to families and society. This review summarizes the epidemiology, treatment strategies, economic burden of HAE, as well as health-related quality of life of patients, aiming to improve the understanding of HAE among clinicians and healthcare decision-makers.

Key words: Angioedemas, hereditary, Cost of illness, Therapy, Quality of life

刘佳谷映桦贺小宁. 遗传性血管性水肿治疗方式与疾病负担研究进展[J]. 中华皮肤科杂志, 2024,e20220205. doi:10.35541/cjd.20220205

Liu Jia, Gu Yinghua, He Xiaoning, . Treatment and disease burden of hereditary angioedema[J]. Chinese Journal of Dermatology,2024,e20220205. doi:10.35541/cjd.20220205

参考文献 47

［1］	Giavina⁃Bianchi P, Arruda LK, Aun MV, et al. Brazilian guidelines for hereditary angioedema management ⁃ 2017 update part 1: definition, classification and diagnosis［J］. Clinics（Sao Paulo）, 2018,73:e310. doi: 10.6061/clinics/2018/e310.
［2］	Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group［J］. Allergy, 2014,69（5）:602⁃616. doi: 10.1111/all.12380.
［3］	Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema⁃The 2017 revision and update［J］. Allergy, 2018,73（8）:1575⁃1596. doi: 10.1111/all.13384.
［4］	Schöffl C, Wiednig M, Koch L, et al. Hereditary angioedema in Austria: prevalence and regional peculiarities［J］. J Dtsch Dermatol Ges, 2019,17（4）:416⁃423. doi: 10.1111/ddg.13815.
［5］	曹阳, 刘爽, 支玉香. 遗传性血管性水肿发病机制研究进展［J］. 中国医学科学院学报, 2020,42（5）:686⁃690. doi: 10.3881/j.issn.1000⁃503X.11407.
［6］	Longhurst HJ, Dempster J, Lorenzo L, et al. Real⁃world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom［J］. Allergy Asthma Clin Immunol, 2018,14:28. doi: 10.1186/s13223⁃018⁃0253⁃x.
［7］	Henao MP, Kraschnewski JL, Kelbel T, et al. Diagnosis and screening of patients with hereditary angioedema in primary care［J］. Ther Clin Risk Manag, 2016,12:701⁃711. doi: 10.2147/TCRM.S86293.
［8］	Gabos G, Nadasan V, Mihaly E, et al. Hereditary angioedema due to C1⁃inhibitor deficiency in Romania: first national study, diagnostic and treatment challenges［J］. Iran J Immunol, 2020,17（3）:226⁃235. doi: 10.22034/iji.2020.85416.1709.
［9］	Bewtra AK, Levy RJ, Jacobson KW, et al. C1⁃inhibitor therapy for hereditary angioedema attacks: prospective patient assessments of health⁃related quality of life［J］. Allergy Asthma Proc, 2012,33（5）:427⁃431. doi: 10.2500/aap.2012.33.3597.
［10］	Xu YY, Zhi YX, Liu RL, et al. Upper airway edema in 43 patients with hereditary angioedema［J］. Ann Allergy Asthma Immunol, 2014,112（6）:539⁃544.e1. doi: 10.1016/j.anai.2014.03. 003.
［11］	Ayazi M, Fazlollahi MR, Mohammadzadeh I, et al. Delayed diagnosis of hereditary angioedema with C1⁃inhibitor deficiency in iranian children and adolescents［J］. Pediatr Allergy Immunol, 2019,30（3）:395⁃398. doi: 10.1111/pai.13028.
［12］	Zanichelli A, Longhurst HJ, Maurer M, et al. Misdiagnosis trends in patients with hereditary angioedema from the real⁃world clinical setting［J］. Ann Allergy Asthma Immunol, 2016,117（4）:394⁃398. doi: 10.1016/j.anai.2016.08.014.
［13］	国家卫生健康委办公厅.国家卫生健康委办公厅关于印发罕见病诊疗指南（2019年版）的通知（EB/OL）.（2019⁃02⁃27）［2021⁃08⁃31］. http://www.nhc.gov.cn/yzygj/s7659/201902/61d06b 4916c348e0810ce1fceb844333.shtml.
［14］	Roche O, Blanch A, Caballero T, et al. Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain［J］. Ann Allergy Asthma Immunol, 2005,94（4）:498⁃503. doi: 10.1016/S1081⁃1206（10）61121⁃0.
［15］	Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: consensus document［J］. Clin Exp Immunol, 2005,139（3）:379⁃394. doi: 10.1111/j.1365⁃2249.2005.02726.x.
［16］	Bygum A. Hereditary angio⁃oedema in Denmark: a nationwide survey［J］. Br J Dermatol, 2009,161（5）:1153⁃1158. doi: 10. 1111/j.1365⁃2133.2009.09366.x.
［17］	Zanichelli A, Arcoleo F, Barca MP, et al. A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy［J］. Orphanet J Rare Dis, 2015,10:11. doi: 10.1186/s13023⁃015⁃0233⁃x.
［18］	Jung JW, Suh DI, Park HJ, et al. Clinical features of hereditary angioedema in Korean patients: a nationwide multicenter study［J］. Int Arch Allergy Immunol, 2018,176（3⁃4）:272⁃279. doi: 10.1159/000488350.
［19］	Bouillet L, Launay D, Fain O, et al. Hereditary angioedema with C1 inhibitor deficiency: clinical presentation and quality of life of 193 French patients［J］. Ann Allergy Asthma Immunol, 2013,111（4）:290⁃294. doi: 10.1016/j.anai.2013.07.012.
［20］	Blasco AJ, Lázaro P, Caballero T, et al. Social costs of icatibant self⁃administration vs. health professional⁃administration in the treatment of hereditary angioedema in Spain［J］. Health Econ Rev, 2013,3（1）:2. doi: 10.1186/2191⁃1991⁃3⁃2.
［21］	Federici C, Perego F, Borsoi L, et al. Costs and effects of on⁃demand treatment of hereditary angioedema in Italy: a prospective cohort study of 167 patients［J］. BMJ Open, 2018,8（7）:e022291. doi: 10.1136/bmjopen⁃2018⁃022291.
［22］	Lumry WR. Hereditary angioedema: the economics of treatment of an orphan disease［J］. Front Med（Lausanne）, 2018,5:22. doi: 10.3389/fmed.2018.00022.
［23］	Busse PJ, Christiansen SC, Birmingham JM, et al. Development of a health⁃related quality of life instrument for patients with hereditary angioedema living in the United States［J］. J Allergy Clin Immunol Pract, 2019,7（5）:1679⁃1683.e7. doi: 10.1016/j.jaip.2018.11.042.
［24］	Bernstein JA, Tyson C, Relan A, et al. Modeling cost⁃effectiveness of on⁃demand treatment for hereditary angioedema attacks［J］. J Manag Care Spec Pharm, 2020,26（2）:203⁃210. doi: 10.18553/jmcp.2019.19217.
［25］	Mendivil J, Murphy R, de la Cruz M, et al. Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey［J］. Orphanet J Rare Dis, 2021,16（1）:94. doi: 10.1186/s13023⁃021⁃01717⁃4.
［26］	Xu YY, Jiang Y, Zhi YX, et al. Clinical features of hereditary angioedema in Chinese patients: new findings and differences from other populations［J］. Eur J Dermatol, 2013,23（4）:500⁃504. doi: 10.1684/ejd.2013.2105.
［27］	Bork K, Siedlecki K, Bosch S, et al. Asphyxiation by laryngeal edema in patients with hereditary angioedema［J］. Mayo Clin Proc, 2000,75（4）:349⁃354. doi: 10.4065/75.4.349.
［28］	Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1⁃INH deficiency［J］. J Allergy Clin Immunol, 2012,130（3）:692⁃697. doi: 10.1016/j.jaci.2012.05.055.
［29］	Cao Y, Liu S, Zhi Y. The natural course of hereditary angioedema in a Chinese cohort［J］. Orphanet J Rare Dis, 2020,15（1）:257. doi: 10.1186/s13023⁃020⁃01526⁃1.
［30］	Lunn ML, Santos CB, Craig TJ. Is there a need for clinical guidelines in the United States for the diagnosis of hereditary angioedema and the screening of family members of affected patients?［J］. Ann Allergy Asthma Immunol, 2010,104（3）:211⁃214. doi: 10.1016/j.anai.2009.12.004.
［31］	Zanichelli A, Magerl M, Longhurst H, et al. Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe［J］. Allergy Asthma Clin Immunol, 2013,9（1）:29. doi: 10.1186/1710⁃1492⁃9⁃29.
［32］	Grumach AS, Longhurst HJ, Aberer W, et al. Pediatricians diagnosed few patients with childhood⁃presented hereditary angioedema: Icatibant Outcome Survey findings［J］. J Allergy Clin Immunol Pract, 2019,7（3）:1078⁃1080. doi: 10.1016/j.jaip. 2018.07.047.
［33］	Betschel S, Badiou J, Binkley K, et al. The International/Canadian Hereditary Angioedema Guideline［J］. Allergy Asthma Clin Immunol, 2019,15:72. doi: 10.1186/s13223⁃019⁃0376⁃8.
［34］	Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency［J］. J Allergy Clin Immunol, 2012,129（2）:308⁃320. doi: 10.1016/j.jaci.2011.11.025.
［35］	Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 Guidelines for the management of hereditary angioedema［J］. J Allergy Clin Immunol Pract, 2021,9（1）:132⁃150.e3. doi: 10.1016/j.jaip.2020.08.046.
［36］	Horiuchi T, Ohi H, Ohsawa I, et al. Guideline for hereditary angioedema（HAE） 2010 by the Japanese Association for Complement Research ⁃ secondary publication［J］. Allergol Int, 2012,61（4）:559⁃562. doi: 10.2332/allergolint.12⁃RAI⁃0471.
［37］	中华医学会变态反应学分会, 中国医师协会变态反应医师分会, 支玉香, 等. 遗传性血管性水肿的诊断和治疗专家共识［J］. 中华临床免疫和变态反应杂志, 2019,13（1）:1⁃4. doi: 10. 3969j.issn.1673⁃8705.2019.01.001.
［38］	Horiuchi T. Guideline for hereditary angioedema（HAE） 2010 by the Japanese Association for Complement Research: points for diagnosis and treatment［J］. Arerugi, 2014,63（6）:749⁃753.
［39］	张凌凡, 赵宇晗, 李智慧, 等. 遗传性血管性水肿治疗药物的临床研究进展［J］. 世界临床药物, 2020,41（4）:319⁃322. doi: 10.13683/j.wph.2020.04.015.
［40］	Wilson DA, Bork K, Shea EP, et al. Economic costs associated with acute attacks and long⁃term management of hereditary angioedema［J］. Ann Allergy Asthma Immunol, 2010,104（4）:314⁃320. doi: 10.1016/j.anai.2010.01.024.
［41］	Petraroli A, Squeglia V, Di Paola N, et al. Home therapy with plasma⁃derived C1 inhibitor: a strategy to improve clinical outcomes and costs in hereditary angioedema［J］. Int Arch Allergy Immunol, 2015,166（4）:259⁃266. doi: 10.1159/000381341.
［42］	Javaud N, Bouillet L, Rabetrano H, et al. Hereditary angioedema: clinical presentation and socioeconomic cost of 200 French patients［J］. J Allergy Clin Immunol Pract, 2019,7（1）:328⁃330. doi: 10.1016/j.jaip.2018.05.036.
［43］	Spanò R, Di Paola N, Bova M, et al. Value co⁃creation in healthcare: evidence from innovative therapeutic alternatives for hereditary angioedema［J］. BMC Health Serv Res, 2018,18（1）:571. doi: 10.1186/s12913⁃018⁃3389⁃y.
［44］	Castaldo AJ, Jervelund C, Corcoran D, et al. Assessing the cost and quality⁃of⁃life impact of on⁃demand⁃only medications for adults with hereditary angioedema［J］. Allergy Asthma Proc, 2021,42（2）:108⁃117. doi: 10.2500/aap.2021.42.200127.
［45］	Liu S, Wang X, Xu Y, et al. Health⁃related quality of life and its risk factors in Chinese hereditary angioedema patients［J］. Orphanet J Rare Dis, 2019,14（1）:191. doi: 10.1186/s13023⁃019⁃1159⁃5.
［46］	Aygören⁃Pürsün E, Bygum A, Beusterien K, et al. Estimation of EuroQol 5⁃Dimensions health status utility values in hereditary angioedema［J］. Patient Prefer Adherence, 2016,10:1699⁃1707. doi: 10.2147/PPA.S100383.
［47］	Engel⁃Yeger B, Farkas H, Kivity S, et al. Health⁃related quality of life among children with hereditary angioedema［J］. Pediatr Allergy Immunol, 2017,28（4）:370⁃376. doi: 10.1111/pai.12712.

[1]	黄和金李馨雅席文文肖霞蒋斌杨锋. 微创旋切术治疗腋臭患者3 000例术后并发症回顾分析[J]. 中华皮肤科杂志, 2026, 59(1): 62-64.
[2]	《疥疮诊疗中国专家共识（版）》编写委员会专家组. 疥疮诊疗中国专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 59(1): 1-8.
[3]	王溯吴晋彤李文钰章程李承新王睿. 低温等离子体治疗小鼠非开放性金黄色葡萄球菌感染性皮肤病的有效性和安全性评价[J]. 中华皮肤科杂志, 2026, 59(1): 44-50.
[4]	项蕾红徐中奕. 真皮获得性斑状色素沉着症的诊疗难点及对策[J]. 中华皮肤科杂志, 2026, 59(1): 74-76.
[5]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会中国中西医结合学会皮肤性病专业委员会中国非公立医疗机构协会皮肤专业委员会. [开放获取] 玫瑰痤疮患者教育指导专家共识（2026版）[J]. 中华皮肤科杂志, 2026, 0(1): 20240725-e20240725.
[6]	姚我汪慧英. [开放获取] 拉那利尤单抗治疗遗传性血管性水肿临床试验的系统综述[J]. 中华皮肤科杂志, 2026, 59(1): 77-81.
[7]	戴叶芹宋秀祖. 毛囊及毛囊细胞移植在白癜风治疗中的应用进展[J]. 中华皮肤科杂志, 2025, 58(9): 882-885.
[8]	周妙妮盛安琪傅丽芳金嵘许文尉晓冬许爱娥. 茶多酚抗氧化凝胶联合窄谱中波紫外线治疗白癜风的疗效及安全性单中心随机对照试验[J]. 中华皮肤科杂志, 2025, 58(9): 834-838.
[9]	徐中奕邢小雪董雅琦张成锋项蕾红. 上海市某三甲医院黄褐斑患者254例临床特征及疗效的回顾性分析[J]. 中华皮肤科杂志, 2025, 58(9): 808-815.
[10]	姜子琪钟菊丹陈廷巧陈瑾. 黄褐斑发病机制及治疗研究进展[J]. 中华皮肤科杂志, 2025, 58(9): 868-872.
[11]	钟洁敏李薇张淑娟杨艳薛如君李欣怡柯娅楠陈晓吟陈荃. 纳米微针与超声波导入氨甲环酸治疗黄褐斑的疗效与安全性比较：一项随机对照研究[J]. 中华皮肤科杂志, 2025, 58(9): 829-833.
[12]	朱婷婷, 李蔚然潘召兵刘昊唐先发朱才红黄鹤群段大威张若晨陈小建汪洋薛倩张菊锐杨丽婧张学军, 黄贺, 张博, . 巴瑞替尼联合芦可替尼乳膏治疗6例进展期非节段型白癜风患者的疗效观察[J]. 中华皮肤科杂志, 2025, 58(9): 856-859.
[13]	罗帅寒天龙海陆前进. 2024年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2025, 58(8): 777-780.
[14]	中国医师协会皮肤科医师分会痤疮学组中国研究型医院学会皮肤科学专业委员会中国中西医结合学会皮肤性病专业委员会痤疮学组. [开放获取] 寻常痤疮临床严重度分级及疗效评价中国专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(8): 709-714.
[15]	薛珂陈佳李斌. 系统性红斑狼疮靶向治疗研究进展[J]. 中华皮肤科杂志, 2025, 58(8): 781-784.

遗传性血管性水肿治疗方式与疾病负担研究进展

Treatment and disease burden of hereditary angioedema

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 47

相关文章 15

Metrics

本文评价

推荐阅读 10